Skip to content
Search

Latest Stories

GPhC highlights best practices for pharmacies providing weight loss services

General Pharmaceutical Council (GPhC) has shared some examples of best and unsafe practices in providing weight loss services by pharmacies that it has come across while inspecting in the recent months.

Under risk management and governance standard, inspector witnessed that pharmacies did not always have adequate risk assessments specific to the weight loss service, including the medicines and treatments they provided. The risk assessment didn’t include consideration and mitigation of any additional risks of the service they provided, such as providing services at a distance.


It was also noted that pharmacies could not always demonstrate that they sought sufficient assurance to verify the reliability of information thoroughly such as the person’s weight or identity. This means that a vulnerable person could inappropriately be prescribed the medication or use another person’s ID to obtain a medicine.

Pharmacies had not picked up prescribing trends, found inspector. These trends may have indicated inappropriate prescribing and supplying to people.

Pharmacies did not proactively audit or review the quality and safety of their weight loss service. This meant that they may not have been aware of opportunities to improve their service and implement best practice, including when things had gone wrong.

GPhC also highlighted some examples of good practices adopted by pharmacies while offering this services. Some pharmacies had specific guidelines and prescribing policies for weight loss treatments, and others required people to consent to information being shared with their regular practitioner, so the practitioner had up to date information and could offer follow up and monitoring.

To reduce risks, some pharmacies did not post every supply of the weight loss treatment to the person and instead required them to collect some or all their supplies from a pharmacy premises, so they could have their height and weight verified.

While sharing examples of unsafe practice in providing weight loss services, Helen Ireland, Chief Pharmaceutical Officer’s clinical fellow and Neha Ramaiya, Senior Clinical Pharmacy Advisor at the GPhC said: "Weight loss medicines such as orlistat, liraglutide and semaglutide can be abused, misused, and overused, so it’s important that pharmacies reduce the risks and safeguard people accessing their weight loss service. When prescribing and supplying these treatments, pharmacy professionals must consider the person’s mental wellbeing as it may play a part in the reason for people requesting these medicines."

Clinical effectiveness standards 

Inspectors identified examples of poor practice, which included inadequate documentation of prescribing rationale with Ozempic (an off-label treatment) and poor recording of clinical interventions. It was noted that some pharmacies provided weight loss treatments solely based on a questionnaire model, without verifying the reliability of the information provided by the person.

While some pharmacies provide treatment to people with a lower BMI than that recommended or was continued despite no reported weight loss over a period of time. For instance, the manufacturing license for liraglutide (Saxenda) requires 5% weight loss after 12 weeks of treatment, which if not achieved should lead to discontinuation of treatment. So, regular follow up and monitoring needs to be undertaken.

some pharmacies did not have adequate mechanisms in place to prevent over supply of weight loss medication, meaning people could receive more medication than needed for a course of treatment

Good practice examples of managing services safely and effectively- Some pharmacies had comprehensive prescribing notes, which were accessible to other prescribers and the pharmacy team, such as the patient’s height and trends in weight to enable a thorough clinical check by another healthcare professional.

Some pharmacies had automated systems to flag when a person may change an answer in a questionnaire to progress a request, so this could inform the prescriber’s decision making.

Some pharmacies had unique consultation and counselling methods such as bespoke information leaflets, administration videos and follow-up by video or telephone.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less